Clinical Trials Logo

Intraperitoneal Paclitaxel clinical trials

View clinical trials related to Intraperitoneal Paclitaxel.

Filter by:
  • None
  • Page 1

NCT ID: NCT06207305 Recruiting - Clinical trials for Intraperitoneal Paclitaxel

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Start date: January 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.

NCT ID: NCT03618758 Completed - Clinical trials for Peritoneal Carcinomatosis

Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

IPLUS
Start date: December 24, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic chemotherapy. Intraperitoneal chemotherapy in combination with systemic chemotherapy is under many clinical trials mainly in Japan, and are showing promising results. This is Korea's first clinical trial on Intraperitoneal Paclitaxel with Systemic mFOLFOX6 chemotherapy.